PressJuly 17, 2023 Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq
PressJuly 17, 2023 COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology
PressJuly 17, 2023 Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement
PressJuly 17, 2023 Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement
PressJuly 14, 2023 Tryp Therapeutics Receives Confirmation From FDA To Proceed With Phase 2A Clinical Trial in Patients With IBS at Massachusetts General Hospital
PressJuly 14, 2023 Beckley Retreats Advances Research to Combat Veteran Suicide Through Psychedelic Retreats
PressJuly 14, 2023 Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybin
PressJuly 14, 2023 BetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression and Announces Closing of Private Placement
PROJuly 13, 2023 Breaking Boundaries, Transforming Markets: A Comprehensive Mid-Year Review of the Psychedelic Sector (PRO REPORT)
PressJuly 12, 2023 Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCT
PressJuly 11, 2023 Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine’s Scientific Advisory Board
PressJuly 11, 2023 Numinus to Present at the Small Cap Growth Virtual Investor Conference on July 13, 2023
PressJuly 11, 2023 American Medical Association Releases Language of First New Current Procedural Terminology Code for Psychedelic Therapies
PressJuly 10, 2023 The Healing Company Uplists to the OTCQB Venture Market and Secures New Strategic Investors
PressJuly 10, 2023 Numinus to Present at the Small Cap Growth Virtual Investor Conference on July 13, 2023
